Clinical Trial Update: Efficacy and Safety of Rizatriptan-Naproxen (10/550 Mg) in the Acute Treatment of Migraine [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the efficacy and safety of rizatriptan-naproxen (10/550 mg) for the acute treatment of migraine has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Rizatriptan-Naproxen combination

Snippet

Sponsor: Eurofarma Laboratorios S.A. | Conditions: Migraine | Phase 3 | Status: COMPLETED